![[Podcast] Trial Trailblazers: Behind clinical breakthroughs](https://imgproxy.divecdn.com/cr_gUY8HHfHKWVfM5mEkCyXB9OzVqKd0L_Zq5ZJQSoM/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlX1BvZGNhc3RfY292ZXIxMzQ2eDcyOV9SMi5wbmc=.webp)
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger became Gilead Sciences’ new chief medical officer this year after the company’s oncology department suffered some prominent setbacks. But the drug development veteran still believes that the virology giant made the right move to branch out into oncology and immunology.
Dietmar Berger became Gilead Sciences’ new chief medical officer this year after the company’s oncology department suffered some prominent setbacks. But the drug development veteran still believes that the virology giant made the right move to branch out into oncology and immunology.
